NASDAQ · APGE
Apogee Therapeutics, Inc.
$135.07$0.00 (0.0%)
Apogee Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.01% below the high.
Loading market information…
NASDAQ · MENS · USD
Stock price
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Jyong Biotech Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 95.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 08:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$135.07$0.00 (0.0%)
Apogee Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.01% below the high.
$40.50$0.00 (0.0%)
Centessa Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 0.15% below the high.
$64.68+$1.21 (+1.91%)
CG Oncology Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.12% below the high.
$50.39-$0.18 (-0.36%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.68% below the high.
$21.63-$0.67 (-3.0%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 42.32% below the high.
$37.41-$0.13 (-0.35%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.51% below the high.
$69.13-$0.17 (-0.25%)
Celcuity Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.22% below the high.
$16.69-$0.35 (-2.05%)
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.89% below the high.
